[11C]Acetate rest–stress protocol to assess myocardial perfusion and oxygen consumption reserve in a model of congestive heart failure in rats
Creators
- 1. Department of Nuclear Medicine and Radiobiology, Université de Sherbrooke and Sherbrooke Molecular Imaging Center, Étienne-LeBel Clinical Research Center, CHUS, Sherbrooke, QC (Canada)
- 2. Division of Nuclear Medicine, Department of Radiology, University of British Columbia, Vancouver, BC (Canada)
Description
This study describes an [11C]acetate rest–stress method to obtain an indirect estimate of myocardial blood flow (MBF) and myocardial oxygen consumption (MVO2) in rats. Doxorubicin cardiotoxicity was used to test the usefulness of this approach for the assessment of congestive heart failure. Methods: [11C]Acetate rest–stress studies have been used in clinical research to assess the capacity of the coronary arteries to respond to stress. In this article, we used this approach to assess the cardiotoxicity of doxorubicin in a rat model. The method was first validated in a group of healthy rats and then used to follow the effect of doxorubicin chemotherapy on cardiac function. The effect of doxorubicin on myocardial perfusion and oxygen consumption reserve was measured at rest and under dobutamine stimulation. Results: Validation of the protocol showed a good correlation between the MBF and MVO2 (r2=.68). The doxorubicin-treated group showed a significant (P=.04) decrease in cardiovascular perfusion reserve at 1.3±0.2 compared with the control animals at 1.6±0.2. Similar results were obtained for the MVO2 reserve (treated 1.8±0.4 vs. controls 2.3±0.3; P=.02). Conclusions: We describe an [11C]acetate PET rest–stress protocol for the assessment of congestive heart failure in rats and its application to the follow-up of cardiotoxicity under doxorubicin chemotherapy. This is a rapid and reliable approach to the measurement of cardiac perfusion and oxygen consumption reserve that could be applied to the development of new strategies to reduce the cardiotoxicity of anthracycline.
Availability note (English)
Available from http://dx.doi.org/10.1016/j.nucmedbio.2011.07.010Additional details
Identifiers
- DOI
- 10.1016/j.nucmedbio.2011.07.010;
- PII
- S0969-8051(11)00190-9;
Publishing Information
- Journal Title
- Nuclear Medicine and Biology
- Journal Volume
- 39
- Journal Issue
- 2
- Journal Page Range
- p. 287-294
- ISSN
- 0969-8051
- CODEN
- NMBIEO
INIS
- Country of Publication
- United Kingdom
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 44008767
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- ACETATES; BLOOD FLOW; CAPACITY; CARBON 11; CHEMOTHERAPY; CORONARIES; DOXORUBICIN; HEART FAILURE; OXYGEN; RADIOPHARMACEUTICALS; RATS; STIMULATION; STRESSES; VALIDATION
- Descriptors DEC
- ANIMALS; ANTIBIOTICS; ANTI-INFECTIVE AGENTS; ANTINEOPLASTIC DRUGS; ARTERIES; BETA DECAY RADIOISOTOPES; BETA-PLUS DECAY RADIOISOTOPES; BLOOD VESSELS; BODY; CARBON ISOTOPES; CARBOXYLIC ACID SALTS; CARDIOVASCULAR SYSTEM; DRUGS; ELEMENTS; EVEN-ODD NUCLEI; ISOTOPES; LABELLED COMPOUNDS; LIGHT NUCLEI; MAMMALS; MATERIALS; MEDICINE; MINUTES LIVING RADIOISOTOPES; NONMETALS; NUCLEI; ORGANIC COMPOUNDS; ORGANS; RADIOACTIVE MATERIALS; RADIOISOTOPES; RODENTS; SYMPTOMS; TESTING; THERAPY; VERTEBRATES
Optional Information
- Copyright
- Copyright (c) 2012 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.